Therapeutics News and Research

RSS

Pro-Pharmaceuticals announces name change to Galectin Therapeutics

Pro-Pharmaceuticals, Inc. today announced that it has changed its name to Galectin Therapeutics Inc. to more accurately reflect the Company's core expertise in galectin science and its leading platform for the creation of galectin inhibitors to treat serious diseases including fibrosis and cancer.

27 May 2011

Investigators receive NIH grant to help move gene therapy for MPS IIIB toward clinical trials

Investigators at Nationwide Children's have received a grant from the National Institutes of Health to help move a therapy for MPS IIIB that has been shown effective in mice toward clinical trials in humans.

26 May 2011

Comprehensive insight into current neural stem cell research and therapies

A new article published by Cell Press in the May 26 issue of the journal Neuron provides comprehensive insight into the current status of neural stem cell research and the sometimes labyrinthine pathways leading to stem cell-based therapies.

26 May 2011

Paxil and Pravachol in combination cause unexpected increase in blood glucose levels

A widely used combination of two common medications may cause unexpected increases in blood glucose levels, according to a study conducted at the Stanford University School of Medicine, Vanderbilt University and Harvard Medical School. Researchers were surprised at the finding because neither of the two drugs - one, an antidepressant marketed as Paxil, and the other, a cholesterol-lowering medication called Pravachol - has a similar effect alone.

26 May 2011

Comtex SmarTrend ranks POZEN as second most efficient pharmaceutical company

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, announced today that Comtex SmarTrend has ranked POZEN as the second most efficient company in the pharmaceutical industry.

25 May 2011

Pathway receives FDA approval to commence PWT33597 Phase 1 study in advanced solid tumors

Pathway Therapeutics, Inc., a company developing novel therapeutics that target the PI3K and mTOR pathways, today announced that the FDA has accepted an IND filing for PWT33597, which allows Pathway to commence Phase 1 clinical testing.

25 May 2011

PPSC, InVivo enter sponsorship deal to support Adaptive Sailing Program for the disabled

InVivo Therapeutics, a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries, today announced that the Company has entered into a sponsorship agreement with Boston-based Piers Park Sailing Center to support a non-profit sailing initiative for the disabled.

25 May 2011

CRT, Cancer Research UK and Centella partner to launch clinical development of CEN-209

Cancer Research UK and Cancer Research Technology - the charity's development and commercialisation arm - have partnered with Centella Therapeutics, Inc. of Palo Alto, California, to develop, manufacture and trial a promising new drug, CEN-209 in cancer patients with solid tumours.

25 May 2011

Elan, Proteostasis create innovative drug discovery initiative for neurodegenerative disorders

Proteostasis Therapeutics and Elan Corporation today announced a strategic business relationship to advance Proteostasis' platform for the discovery and development of disease-modifying, small molecule drugs and diagnostics for the treatment of neurodegenerative disorders such as Parkinson's, Huntington's, multiple sclerosis and amyotrophic lateral sclerosis, and a broad array of dementia-related diseases including Alzheimer's.

25 May 2011

Evotec, PsychoGenics partner to offer integrated CNS drug discovery solutions

PsychoGenics Inc. today announced that it has entered into a strategic alliance with Evotec AG to provide integrated CNS drug discovery solutions to pharmaceutical and biotech companies.

25 May 2011

ImmunoCellular to present new ICT-107 Phase I trial data in glioblastoma multiforme at ASCO 2011

ImmunoCellular Therapeutics, Ltd today announced it will be presenting new data from the Phase I clinical trial of ICT-107, the Company's lead cancer vaccine candidate for the treatment of glioblastoma multiforme.

25 May 2011

Scientists develop quick, low-cost microchip for immune monitoring and clinical applications

There's a wealth of health information hiding in the human immune system. Accessing it, however, can be very challenging, as the many and complex roles that the immune system plays can mask the critical information that is relevant to addressing specific health issues.

25 May 2011

Proteros, IP-K partner for structure-based drug discovery services in the field of infectious diseases

Proteros Biostructures GmbH announced today that it has entered into a service agreement with Institut Pasteur Korea (IP-K) under which Proteros will provide structure-based drug discovery services to IP-K.

25 May 2011

Scientists mimic dyskeratosis congenita through study of undifferentiated iPS cells

A rare genetic disease called dyskeratosis congenita, caused by the rapid shortening of telomeres, can be mimicked through the study of undifferentiated induced pluripotent stem cells, according to new findings from the Stanford University School of Medicine.

24 May 2011

Accelerator announces Series A financing of Oncofactor

Accelerator Corporation, a privately held, venture-capital-backed biotechnology investment and development company, announced today the Series A financing of Oncofactor Corporation. This is the twelfth company backed by Accelerator and its first investment based on internal intellectual property developed at Accelerator.

24 May 2011

Exosome Diagnostics announces expansion of scientific advisory board

Exosome Diagnostics, a leading developer of biofluid based molecular diagnostic tests for use in personalised medicine, today announced the appointments of Bob Carter MD, Carlos Cordon-Cardo MD, PhD, Keith Flaherty MD, John Quackenbush, PhD; to its Scientific Advisory Board (SAB).

24 May 2011

VBL to present updated VB-111 Phase 1 trial results in advanced metastatic cancer at ASCO 2011

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced that it will present updated results for a Phase 1 study of VB-111 in patients with advanced metastatic cancer at the upcoming Annual Meeting of the American Society of Clinical Oncology, taking place June 3-7, 2011, at McCormick Place in Chicago.

24 May 2011

Probiotic bacterial protein could offer new oral therapeutic option for inflammatory bowel disorders

A protein isolated from beneficial bacteria found in yogurt and dairy products could offer a new, oral therapeutic option for inflammatory bowel disorders, suggests a study led by Vanderbilt University Medical Center researcher Fang Yan, M.D., Ph.D.

24 May 2011

Substantial portion of patients with headaches improve without treatment

Headache is a very common complaint, with over 90% of all persons experiencing a headache at some time in their lives. Headaches commonly are tension-type (TTH) or migraine. They have high socioeconomic impact and can disturb most daily activities. Treatments range from pharmacologic to behavioral interventions.

23 May 2011

Sangamo announces presentations of ZFP Therapeutics data at ASGCT 2011

Sangamo BioSciences, Inc. announced today that data from clinical, preclinical and research-stage programs focused on the development of zinc finger DNA-binding protein Therapeutics were described in twenty presentations given by Sangamo scientists and collaborators at the 14th Annual Meeting of the American Society of Gene and Cell Therapy.

23 May 2011

Therapeutics News and Research

Pro-Pharmaceuticals announces name change to Galectin Therapeutics

Investigators receive NIH grant to help move gene therapy for MPS IIIB toward clinical trials

Comprehensive insight into current neural stem cell research and therapies

Paxil and Pravachol in combination cause unexpected increase in blood glucose levels

Comtex SmarTrend ranks POZEN as second most efficient pharmaceutical company

Pathway receives FDA approval to commence PWT33597 Phase 1 study in advanced solid tumors

PPSC, InVivo enter sponsorship deal to support Adaptive Sailing Program for the disabled

CRT, Cancer Research UK and Centella partner to launch clinical development of CEN-209

Elan, Proteostasis create innovative drug discovery initiative for neurodegenerative disorders

Evotec, PsychoGenics partner to offer integrated CNS drug discovery solutions

ImmunoCellular to present new ICT-107 Phase I trial data in glioblastoma multiforme at ASCO 2011

Scientists develop quick, low-cost microchip for immune monitoring and clinical applications

Proteros, IP-K partner for structure-based drug discovery services in the field of infectious diseases

Scientists mimic dyskeratosis congenita through study of undifferentiated iPS cells

Accelerator announces Series A financing of Oncofactor

Exosome Diagnostics announces expansion of scientific advisory board

VBL to present updated VB-111 Phase 1 trial results in advanced metastatic cancer at ASCO 2011

Probiotic bacterial protein could offer new oral therapeutic option for inflammatory bowel disorders

Substantial portion of patients with headaches improve without treatment

Sangamo announces presentations of ZFP Therapeutics data at ASGCT 2011

Advancing therapeutic biopolymer development eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News